keyword
MENU ▼
Read by QxMD icon Read
search

V2 receptor

keyword
https://www.readbyqxmd.com/read/27921039/clinical-manifestation-and-management-of-adpkd-in-western-countries
#1
REVIEW
Claudia Sommerer, Martin Zeier
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease in Western countries. The prevalence is between 2.4/10,000 and 3.9/10,000. ADPKD represents a systemic disease resulting in deterioration in renal function. Until now, mutations in two genes (PKD1 and PKD2) have been identified. Recently, the European Medicines Agency (EMA) approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency connected with ADPKD in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease...
October 2016: Kidney Diseases
https://www.readbyqxmd.com/read/27920153/urine-osmolality-response-to-tolvaptan-and-outcome-in-autosomal-dominant-polycystic-kidney-disease-results-from-the-tempo-3-4-trial
#2
Olivier Devuyst, Arlene B Chapman, Ron T Gansevoort, Eiji Higashihara, Ronald D Perrone, Vicente E Torres, Jaime D Blais, Wen Zhou, John Ouyang, Frank S Czerwiec
The vasopressin-cAMP-osmolality axis is abnormal in autosomal dominant polycystic kidney disease (ADPKD). In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 Trial, a 3-year randomized, placebo-controlled trial in adults, the vasopressin V2 receptor antagonist tolvaptan slowed ADPKD progression in patients with preserved GFR. Here, we investigated the determinants of baseline urine osmolality (Uosm) and its value as a severity marker of ADPKD, the factors influencing the response to tolvaptan, and whether change in Uosm associated with key trial end points...
December 5, 2016: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/27916790/announcement-ueda-heart-award-for-2016
#3
(no author information available yet)
We are pleased to announce that the following 4 articles have been selected for the the UEDA Heart Awards for the Year 2016.First PlaceDelivery of Imatinib-Incorporated Nanoparticles into Lungs Suppresses the Development of Monocrotaline-Induced Pulmonary Arterial HypertensionSatoshi Akagi, Kazufumi Nakamura, Daiji Miura, Yukihiro Saito, Hiromi Matsubara, Aiko Ogawa, Tetsuya Matoba, Kensuke Egashira, Hiroshi ItoInt Heart J 2015 ; 56(3) : 354-359Second PlaceVasopressin V2 Receptor Antagonist Tolvaptan Is Effective in Heart Failure Patients With Reduced Left Ventricular Systolic Function and Low Blood PressureSatoshi Suzuki, Akiomi Yoshihisa, Takayoshi Yamaki, Koichi Sugimoto, Hiroyuki Kunii, Kazuhiko Nakazato, Yukihiko Abe, Tomiyoshi Saito, Takayuki Ohwada, Hitoshi Suzuki, Shu-ichi Saitoh, Isao Kubota, Yasuchika Takeishi, on behalf of the AVCMA investigatorsInt Heart J 2015 ; 56(2) : 213-218Third PlaceWaon Therapy Improves Quality of Life as Well as Cardiac Function and Exercise Capacity in Patients With Chronic Heart FailureMitsuo Sobajima, Takashi Nozawa, Yasutaka Fukui, Hiroyuki Ihori, Takashi Ohori, Nozomu Fujii, Hiroshi InoueInt Heart J 2015 ; 56(2) : 203-208Association of Fish Consumption-Derived Ratio of Serum n-3 to n-6 Polyunsaturated Fatty Acids and Cardiovascular Risk With the Prevalence of Coronary Artery Disease : A Cross-Sectional Pilot StudyShigemasa Tani, Atsuhiko Takahashi, Ken Nagao, Atsushi HirayamaInt Heart J 2015 ; 56(3) : 260-268November 2016International Heart Journal Association...
2016: International Heart Journal
https://www.readbyqxmd.com/read/27909962/efficiency-of-osmotic-concentration-after-combined-treatment-with-vasopressin-and-blockage-of-prostaglandin-synthesis
#4
V A Lavrinenko, A V Babina
We performed a complex functional study of the effects of prostaglandin synthesis blockage with diclofenac on manifestation of the hydroosmotic effect of vasopressin V2-receptor agonist desmopressin in the kidneys of Wistar rats with normal synthesis of endogenous vasopressin and homozygous Brattleboro rats with hereditary impaired synthesis of neurohypophyseal hormone vasopressin. Blockage of prostaglandin synthesis led to more pronounced increase in urine osmolality in Brattleboro rats than in Wistar rats due to elevation of not only urine but also sodium gradient at the expense of elimination of the inhibitory effect of prostaglandins on sodium reabsorption and membrane permeability for urine...
December 2, 2016: Bulletin of Experimental Biology and Medicine
https://www.readbyqxmd.com/read/27896572/identification-of-novel-mutations-in-hfe-hfe2-tfr2-and-slc40a1-genes-in-chinese-patients-affected-by-hereditary-hemochromatosis
#5
Yongwei Wang, Yali Du, Gang Liu, Shanshan Guo, Bo Hou, Xianyong Jiang, Bing Han, Yanzhong Chang, Guangjun Nie
Hereditary hemochromatosis (HH) is a group of inherited iron-overload disorders associated with pathogenic defects in the genes encoding hemochromatosis (HFE), hemojuvelin (HJV/HFE2), hepcidin (HAMP), transferrin receptor 2 (TfR2), and ferroportin (FPN1/SLC40A1) proteins, and the clinical features are well described. However, there have been only a few detailed reports of HH in Chinese populations. Thus, there is insufficient patient information for population-based analyses in Chinese populations or comparative studies among different ethical groups...
November 28, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27857840/tolvaptan-use-during-hyperhydration-in-paediatric-intracranial-lymphoma-with-siadh
#6
Ruben H Willemsen, Violeta Delgado-Carballar, Daniela Elleri, Ajay Thankamony, G A Amos Burke, James C Nicholson, David B Dunger
: An 11-year-old boy developed severe syndrome of inappropriate antidiuretic hormone secretion (SIADH) after diagnosis of an intracranial B-cell lymphoma. His sodium levels dropped to 118-120 mmol/L despite 70% fluid restriction. For chemotherapy, he required hyperhydration, which posed a challenge because of severe hyponatraemia. Tolvaptan is an oral, highly selective arginine vasopressin V2-receptor antagonist, which has been licensed in adults for the management of SIADH and has been used in treating paediatric heart failure...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27856088/tolvaptan-and-kidney-pain-in-patients-with-autosomal-dominant%C3%A2-polycystic-kidney-disease-secondary-analysis-from%C3%A2-a-randomized-controlled-trial
#7
Niek F Casteleijn, Jaime D Blais, Arlene B Chapman, Frank S Czerwiec, Olivier Devuyst, Eiji Higashihara, Anna M Leliveld, John Ouyang, Ronald D Perrone, Vicente E Torres, Ron T Gansevoort
BACKGROUND: Kidney pain is a common complication in patients with autosomal dominant polycystic kidney disease (ADPKD), and data from the TEMPO 3:4 trial suggested that tolvaptan, a vasopressin V2 receptor antagonist, may have a positive effect on kidney pain in this patient group. Because pain is difficult to measure, the incidence of kidney pain leading to objective medical interventions was used in the present study to assess pain. STUDY DESIGN: Secondary analysis from a randomized controlled trial...
November 14, 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/27818782/randomized-pilot-trial-comparing-tolvaptan-with-furosemide-on-renal-and-neurohumoral-effects-in-acute-heart-failure
#8
Kentaro Jujo, Katsumi Saito, Issei Ishida, Yuho Furuki, Ahsung Kim, Yuki Suzuki, Haruki Sekiguchi, Junichi Yamaguchi, Hiroshi Ogawa, Nobuhisa Hagiwara
AIMS: Loop diuretics are first-line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal function, and sympathetic nervous and renin-angiotensin system activation. We tested whether tolvaptan, a vasopressin V2-receptor antagonist, could reduce unfavourable furosemide-induced effects during CHF treatment. METHODS AND RESULTS: Sixty patients emergently hospitalized owing to CHF-induced dyspnea were randomly assigned to receive either 40 mg intravenous furosemide daily or 7...
September 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27795431/broadly-neutralising-antibodies-display-superior-potential-over-non-neutralising-antibodies-in-preventing-hiv-1-infection-of-mucosal-tissue
#9
Hannah M Cheeseman, Natalia J Olejniczak, Paul M Rogers, Abbey B Evans, Deborah F L King, Paul Ziprin, Hua-Xin Liao, Barton F Haynes, Robin J Shattock
: Definition of the key parameters mediating effective antibody blocking of HIV-1 acquisition within mucosal tissue may prove critical to effective vaccine development and the prophylactic use of monoclonal antibodies. Although direct antibody-mediated neutralisation is highly effective against cell-free virus, antibodies targeting different sites of envelope vulnerability may display differential activity against mucosal infection. Non-neutralising antibodies (nnAbs) may also impact on mucosal transmission events through Fc-gamma receptor (FcγR)-mediated inhibition...
October 19, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27792681/distinct-hiv-1-neutralization-potency-profiles-of-ibalizumab-based-bispecific-antibodies
#10
Ruijiang Song, Craig Pace, Michael S Seaman, Qing Fang, Ming Sun, Chasity D Andrews, Amos Wu, Neal N Padte, David D Ho
BACKGROUND: Preexposure prophylaxis using antiretroviral agents has been shown to effectively prevent human immunodeficiency virus type 1 (HIV-1) acquisition in high-risk populations. However, the efficacy of these regimens is highly variable, which is thought to be largely due to the varying degrees of adherence to a daily intervention in the populations. Passive immunization using broadly neutralizing antibodies (bNAbs) against HIV-1, with their relatively long half-life and favorable safety profile, could provide an alternative to daily preexposure prophylaxis...
December 1, 2016: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27788216/selepressin-and-arginine-vasopressin-do-not-display-cardiovascular-risk-in-atherosclerotic-rabbit
#11
Olivier Boucheix, Robert Blakytny, Gerard Haroutunian, Marie Henriksson, Regent Laporte, Stephane Milano, Torsten M Reinheimer
BACKGROUND: Septic shock remains associated with significant mortality rates. Arginine vasopressin (AVP) and analogs with V1A receptor agonist activity are increasingly used to treat fluid-resistant vasodilatory hypotension, including catecholamine-refractory septic shock. Clinical studies have been restricted to healthy volunteers and catecholamine-refractory septic shock patients excluding subjects with cardiac co-morbidities because of presumed safety issues. The novel selective V1A receptor agonist selepressin, with short half-life, has been designed to avoid V2 receptor-related complications and long-term V1A receptor activation...
2016: PloS One
https://www.readbyqxmd.com/read/27784066/trpv2-channels-contribute-to-stretch-activated-cation-currents-and-myogenic-constriction-in-retinal-arterioles
#12
Mary K McGahon, José A Fernández, Durga P Dash, Jon McKee, David A Simpson, Alex V Zholos, J Graham McGeown, Tim M Curtis
Purpose: Activation of the transient receptor potential channels, TRPC6, TRPM4, and TRPP1 (PKD2), has been shown to contribute to the myogenic constriction of cerebral arteries. In the present study we sought to determine the potential role of various mechanosensitive TRP channels to myogenic signaling in arterioles of the rat retina. Methods: Rat retinal arterioles were isolated for RT-PCR, Fura-2 Ca2+ microfluorimetry, patch-clamp electrophysiology, and pressure myography studies...
October 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27773680/vasopressin-v1a-receptor-mediates-cell-proliferation-through-grk2-egfr-erk1-2-pathway-in-a7r5-cells
#13
Lingling Zhang, Xiaojun Wang, Hong Cao, Yunxuan Chen, Xianfan Chen, Xi Zhao, Feifei Xu, Yifan Wang, Anthony Yiu-Ho Woo, Weizhong Zhu
Abnormal proliferation and hypertrophy of vascular smooth muscle (VSMC), as the main structural component of the vasculature, is an important pathological mechanism of hypertension. Recently, increased levels of arginine vasopressin (AVP) and copeptin, the C-terminal fragment of provasopressin, have been shown to correlate with the development of preeclampsia. AVP targets on the Gq-coupled vasopressin V1A receptor and the Gs-coupled V2 receptor in VSMC and the kidneys to regulate vascular tone and water homeostasis...
October 20, 2016: European Journal of Pharmacology
https://www.readbyqxmd.com/read/27746425/predictors-of-the-effect-of-tolvaptan-on-the-prognosis-of-cirrhosis
#14
Takuya Iwamoto, Masaki Maeda, Takuro Hisanaga, Issei Saeki, Koichi Fujisawa, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treated at our hospital from September 2013 to April 2015. Results The primary disease was hepatitis C in 20 patients, hepatitis B in 2, nonalcoholic steatohepatitis in 2 and others in 2; and 12 had hepatocellular carcinoma...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27746291/limited-efficacy-of-tolvaptan-in-patients-with-cirrhosis-and-severe-hyponatremia-real-life-experience
#15
Elisa Pose, Elsa Solà, Salvatore Piano, Elisabetta Gola, Isabel Graupera, Mónica Guevara, Andrés Cárdenas, Paolo Angeli, Pere Ginès
BACKGROUND: Vaptans, vasopressin selective V2-receptor antagonist, represent the first pharmacological approach to the treatment of hypervolemic hyponatremia in cirrhosis. However, information on the use of vaptans for patients with cirrhosis and hyponatremia in a real-life scenario is very limited. Therefore, this study evaluated the effect of tolvaptan on serum sodium in patients with cirrhosis and severe hypervolemic hyponatremia. METHODS: Nine patients with cirrhosis and serum sodium <125mEq/L were included...
October 13, 2016: American Journal of Medicine
https://www.readbyqxmd.com/read/27742514/transient-diabetes-insipidus-after-discontinuation-of-vasopressin-in-neurological-icu-patients-case-series-and-literature-review
#16
Michael A Bohl, James Forseth, Peter Nakaji
BACKGROUND: Arginine vasopressin (AVP) is a common second-line or third-line vasopressor used in critically ill neurosurgical patients. Neurosurgical indications include hyperdynamic therapy for vasospasm, maintenance of cerebral perfusion pressure in patients with intracranial hypertension, and prevention of hypotension in patients with sepsis. CASE DESCRIPTION: A series of six neurosurgical patients receiving AVP infusions developed severe but transient diabetes insipidus (tDI) after cessation of AVP...
October 11, 2016: World Neurosurgery
https://www.readbyqxmd.com/read/27725533/dual-impact-of-tolvaptan-on-intracellular-and-extracellular-water-in-chronic-kidney-disease-patients-with-fluid-retention
#17
Takahiro Masuda, Takuya Murakami, Yusuke Igarashi, Kyochika Okabe, Takahisa Kobayashi, Shin-Ichi Takeda, Takako Saito, Chuji Sekiguchi, Yasuharu Miyazawa, Tetsu Akimoto, Osamu Saito, Shigeaki Muto, Daisuke Nagata
Objective Tolvaptan, an oral selective V2-receptor antagonist, is a water diuretic that ameliorates fluid retention with a lower risk of a worsening renal function than conventional loop diuretics. Although loop diuretics predominantly decrease extracellular water (ECW) compared with intracellular water (ICW), the effect of tolvaptan on fluid distribution remains unclear. We therefore examined how tolvaptan changes ICW and ECW in accordance with the renal function. Methods Six advanced chronic kidney disease patients (stage 4 or 5) with fluid retention were enrolled in this study...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27721113/a-vitamin-d-pathway-gene-gene-interaction-affects-low-density-lipoprotein-cholesterol-levels
#18
Nathália Grave, Luciana Tovo-Rodrigues, Janaína da Silveira, Diego Luiz Rovaris, Simone Morelo Dal Bosco, Verônica Contini, Júlia Pasqualini Genro
Much evidence suggests an association between vitamin D deficiency and chronic diseases such as obesity and dyslipidemia. Although genetic factors play an important role in the etiology of these diseases, only a few studies have investigated the relationship between vitamin D-related genes and anthropometric and lipid profiles. The aim of this study was to investigate the association of three vitamin D-related genes with anthropometric and lipid parameters in 542 adult individuals. We analyzed the rs2228570 polymorphism in the vitamin D receptor gene (VDR), rs2134095 in the retinoid X receptor gamma gene (RXRG) and rs7041 in the vitamin D-binding protein gene (GC)...
August 15, 2016: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/27704665/predictive-parameter-of-tolvaptan-effectiveness-in-cirrhotic-ascites
#19
Hideto Kawaratani, Hiroshi Fukui, Kei Moriya, Ryuichi Noguchi, Tadashi Namisaki, Masakazu Uejima, Mitsuteru Kitade, Kosuke Takeda, Yasushi Okura, Kosuke Kaji, Norihisa Nishimura, Hiroaki Takaya, Yousuke Aihara, Yasuhiko Sawada, Shinya Sato, Kenichiro Seki, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji
AIMS: The efficacy of the vasopressin V2 receptor antagonist tolvaptan for difficult-to-treat cirrhotic ascites has recently been reported. However, its effect is variable among patients. This study aimed to clarify the predictive factors for obtaining a good response to tolvaptan in patients with difficult-to-treat ascites. METHODS: Data were collected from 50 patients with liver cirrhosis having ascites (hepatitis B, n = 1; hepatitis C, n = 22; alcoholism, n = 11; and others, n = 16) after treatment with tolvaptan (3...
October 5, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27684044/continuous-iv-infusion-is-the-choice-treatment-route-for-arginine-vasopressin-receptor-blocker-conivaptan-in-mice-to-study-stroke-evoked-brain-edema
#20
Emil Zeynalov, Susan M Jones, J Paul Elliott
Stroke is one of the major causes of morbidity and mortality in the world. Stroke is complicated by brain edema and other pathophysiological events. Among the most important players in the development and evolution of stroke-evoked brain edema is the hormone arginine-vasopressin and its receptors, V1a and V2. Recently, the V1a and V2 receptor blocker conivaptan has been attracting attention as a potential drug to reduce brain edema after stroke. However, animal models which involve conivaptan applications in stroke research need to be modified based on feasible routes of administration...
2016: Journal of Visualized Experiments: JoVE
keyword
keyword
3018
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"